On August 7, Hims & Hers Health Inc. fell 5.06% in regular trading, trading at $30.05 per share with turnover of $114 million. The decline was driven by a law firm announcing a federal securities law violation investigation on behalf of investors seeking potential losses, compounding existing legal pressures ahead of the company's Q2 earnings report scheduled for August 10.

The investigation adds to an already challenging legal backdrop. The U.S. Federal Trade Commission filed suit against the company in late July, alleging it improperly shared users' health data with Meta Platforms and Snap for advertising purposes, as well as citing issues with billing practices and subscription cancellation policies. The FTC news initially triggered a 12%-plus single-day decline. Hims & Hers has firmly denied the allegations, stating the lawsuit ignores substantial evidence provided during nearly three years of investigation.

Market consensus expects Q2 revenue of approximately $700 million, representing 26.88% year-over-year growth, with adjusted EPS of -$0.01. The convergence of unresolved litigation risk and earnings uncertainty appears to be suppressing investor sentiment.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)